Project Optimus: How to Prepare for Success
For some time now, cancer drug developers have known “Project Optimus” and new dose optimization…
CertaraNovember 28, 2022
The eCTD Submission Process: Tips and Tricks for Drug Development Success
Our experts compiled the tips and best practices you need to know for a successful…
CertaraNovember 22, 2022
Tips & Tricks for Data Management in Phoenix WinNonlin
Learn some tips & tricks for the Data Wizard, a data management tool in Phoenix,…
CertaraNovember 18, 2022
Tips to Use Phoenix WinNonlin More Efficiently
Certara’s Phoenix™ Pharmacokinetic and Pharmacodynamic (PK/PD) Platform is the single, interoperable hub for sharing pre-clinical…
CertaraNovember 7, 2022
Arsenal Capital Partners Increases Investment in Global Biosimulation Leader Certara with $449M Stock Purchase
Arsenal will acquire approximately 30M shares at $15 per share from funds controlled by EQT…
CertaraNovember 7, 2022
The Role of PBPK Modeling & Simulation in Infants & Neonates
Many factors make it challenging to obtain adequate pediatric samples for use in drug development…
CertaraNovember 4, 2022
Why you should select your drug formulation before starting clinical studies
Drug developers often rush through the discovery process to get into human testing. Most are…
CertaraOctober 28, 2022
Accelerating Market Access with Data-Driven Payer Engagement
Using data visualizations to improve access to payers. With the switch to more digital environments,…
CertaraOctober 25, 2022
Applications of PBPK modelling for regulatory submissions: case studies involving DDIs, transporters and special populations
Over the past two decades, there have been transformative changes in our approach to using…
CertaraOctober 20, 2022
Simultaneous FDA & EMA Submissions for Drug Approvals
Is there a better way? The question always breeds critical thinking and often leads to…
CertaraOctober 19, 2022
